Brentuximab vedotin

Property	Value
rdf:type	owl:NamedIndividual Antibody-drug conjugate Orphan drug Therapeutic monoclonal antibody Drug: Br Drug granted breakthrough therapy designation Takeda Pharmaceutical Company brand
rdfs:label	Brentuximab vedotin
owl:sameAs	dbr:Brentuximab_vedotin
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/Antibody-drug_conjugate http://en.wikipedia.org/wiki/Seagen http://en.wikipedia.org/wiki/Category:Antibody-drug_conjugates http://en.wikipedia.org/wiki/Category:Orphan_drugs http://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies http://en.wikipedia.org/wiki/Category:Takeda_Pharmaceutical_Company_brands http://en.wikipedia.org/wiki/Monoclonal_antibody_therapy http://en.wikipedia.org/wiki/List_of_drugs_granted_breakthrough_therapy_designation http://en.wikipedia.org/wiki/Marine_pharmacognosy http://en.wikipedia.org/wiki/List_of_drugs:_Br http://en.wikipedia.org/wiki/Monomethyl_auristatin_E
skos:prefLabel	Brentuximab vedotin
skos:altLabel	ADCETRIS Brentuximab Vedotin (SGN-35) Brentuximab_vedotin#Clinical_trials brentuximab vedotin
clgo:alternativeName	Adcetris
clgo:casNumber	914088-09-8
clgo:drugbank	DB08870
clgo:fdaUniiCode	7XL5ISS668
clgo:medlinePlus	a611052
clgo:chemicalFormula	C6476H9930N1690O2030S40 (C68H105N11O15)3–5
is clgo:product of	Seagen

About: clgr:Brentuximab_vedotin